Annual CFO:
-$116.59M-$73.81M(-172.54%)Summary
- As of today, MLTX annual cash from operations is -$116.59 million, with the most recent change of -$73.81 million (-172.54%) on December 31, 2024.
- During the last 3 years, MLTX annual cash from operations has fallen by -$81.41 million (-231.45%).
- MLTX annual cash from operations is now -36713.17% below its all-time high of -$316.70 thousand, reached on December 1, 2020.
Performance
MLTX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly CFO:
-$44.54M+$9.99M(+18.31%)Summary
- As of today, MLTX quarterly cash from operations is -$44.54 million, with the most recent change of +$9.99 million (+18.31%) on September 30, 2025.
- Over the past year, MLTX quarterly cash from operations has dropped by -$19.27 million (-76.23%).
- MLTX quarterly cash from operations is now -41220.04% below its all-time high of -$107.80 thousand, reached on March 1, 2021.
Performance
MLTX Quarterly Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFO:
-$185.69M-$19.27M(-11.58%)Summary
- As of today, MLTX TTM cash from operations is -$185.69 million, with the most recent change of -$19.27 million (-11.58%) on September 30, 2025.
- Over the past year, MLTX TTM cash from operations has dropped by -$105.23 million (-130.79%).
- MLTX TTM cash from operations is now -58531.73% below its all-time high of -$316.70 thousand, reached on December 1, 2020.
Performance
MLTX TTM Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
MLTX Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | -172.5% | -76.2% | -130.8% |
| 3Y3 Years | -231.4% | -376.3% | -258.8% |
| 5Y5 Years | -10000.0% | - | - |
MLTX Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | -231.4% | at low | -393.6% | +18.3% | -341.8% | at low |
| 5Y | 5-Year | >-9999.0% | at low | >-9999.0% | +18.3% | >-9999.0% | at low |
| All-Time | All-Time | >-9999.0% | at low | >-9999.0% | +18.3% | >-9999.0% | at low |
MLTX Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2025 | - | -$44.54M(+18.3%) | -$185.69M(-11.6%) |
| Jun 2025 | - | -$54.53M(-43.0%) | -$166.42M(-19.1%) |
| Mar 2025 | - | -$38.14M(+21.3%) | -$139.78M(-19.9%) |
| Dec 2024 | -$116.59M(-172.5%) | -$48.47M(-91.8%) | -$116.59M(-44.9%) |
| Sep 2024 | - | -$25.27M(+9.4%) | -$80.46M(-24.9%) |
| Jun 2024 | - | -$27.89M(-86.6%) | -$64.43M(-32.3%) |
| Mar 2024 | - | -$14.95M(-21.1%) | -$48.70M(-13.8%) |
| Dec 2023 | -$42.78M | -$12.34M(-33.4%) | -$42.78M(-1.8%) |
| Sep 2023 | - | -$9.25M(+23.9%) | -$42.03M(+0.2%) |
| Jun 2023 | - | -$12.16M(-34.7%) | -$42.13M(+17.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2023 | - | -$9.02M(+22.2%) | -$50.73M(+9.2%) |
| Dec 2022 | -$55.89M(-58.9%) | -$11.60M(-24.0%) | -$55.89M(-8.0%) |
| Sep 2022 | - | -$9.35M(+55.0%) | -$51.75M(-16.5%) |
| Jun 2022 | - | -$20.76M(-46.3%) | -$44.42M(+9.8%) |
| Mar 2022 | - | -$14.19M(-90.4%) | -$49.25M(-40.0%) |
| Dec 2021 | -$35.18M(>-9900.0%) | -$7.45M(-269.2%) | -$35.18M(-25.4%) |
| Sep 2021 | - | -$2.02M(+92.1%) | -$28.04M(-7.8%) |
| Jun 2021 | - | -$25.60M(>-9900.0%) | -$26.02M(-6029.9%) |
| Mar 2021 | - | -$107.80K(+66.0%) | -$424.50K(-34.0%) |
| Dec 2020 | -$316.70K | -$316.70K | -$316.70K |
FAQ
- What is MoonLake Immunotherapeutics annual cash from operations?
- What is the all-time high annual cash from operations for MoonLake Immunotherapeutics?
- What is MoonLake Immunotherapeutics annual cash from operations year-on-year change?
- What is MoonLake Immunotherapeutics quarterly cash from operations?
- What is the all-time high quarterly cash from operations for MoonLake Immunotherapeutics?
- What is MoonLake Immunotherapeutics quarterly cash from operations year-on-year change?
- What is MoonLake Immunotherapeutics TTM cash from operations?
- What is the all-time high TTM cash from operations for MoonLake Immunotherapeutics?
- What is MoonLake Immunotherapeutics TTM cash from operations year-on-year change?
What is MoonLake Immunotherapeutics annual cash from operations?
The current annual cash from operations of MLTX is -$116.59M
What is the all-time high annual cash from operations for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics all-time high annual cash from operations is -$316.70K
What is MoonLake Immunotherapeutics annual cash from operations year-on-year change?
Over the past year, MLTX annual cash from operations has changed by -$73.81M (-172.54%)
What is MoonLake Immunotherapeutics quarterly cash from operations?
The current quarterly cash from operations of MLTX is -$44.54M
What is the all-time high quarterly cash from operations for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics all-time high quarterly cash from operations is -$107.80K
What is MoonLake Immunotherapeutics quarterly cash from operations year-on-year change?
Over the past year, MLTX quarterly cash from operations has changed by -$19.27M (-76.23%)
What is MoonLake Immunotherapeutics TTM cash from operations?
The current TTM cash from operations of MLTX is -$185.69M
What is the all-time high TTM cash from operations for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics all-time high TTM cash from operations is -$316.70K
What is MoonLake Immunotherapeutics TTM cash from operations year-on-year change?
Over the past year, MLTX TTM cash from operations has changed by -$105.23M (-130.79%)